Phase I study to evaluate the safety, tolerability and preliminary efficacy of rivoceranib plus paclitaxel in advanced gastric or gastroesophageal junction (GEJ) cancer

被引：0
|
作者：
Ryu, M. H. [1 ]
Pande, A. [2 ]
Kim, J. H. [2 ]
Kang, Y-K. [1 ]
机构：
[1] Univ Ulsan, Oncol Dept, Asan Med Ctr, Coll Med, Seoul, South Korea
[2] Elevar Therapeut, Clin Res, Salt Lake City, UT USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1237P
引用
收藏
页码：S1114 / S1114
页数：1
相关论文
共 50 条
  • [1] Envafolimab plus chemotherapy in advanced gastric or gastroesophageal junction (G/GEJ) cancer.
    Yin, Xianli
    Zhang, Yun
    Deng, Yanhong
    Xu, Nong
    Xu, Jianming
    Li, Lei
    Song, Xiaotong
    Lu, Haolan
    Gong, John
    Liu, Dongfang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] A phase 1 study to evaluate the safety and preliminary efficacy of minnelide given alone or in combination with paclitaxel in advanced gastric cancer
    Lim, Sung Hee
    Saluja, Ashok K.
    Hong, Jung Yong
    Kim, Seung Tae
    Lavania, Shweta
    Pandey, Somnath
    Gupta, Vineet K.
    Velagapudi, Mohana
    Lee, Jeeyun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Study on the efficacy and safety of sintilimab combined with nab-paclitaxel as second-line treatment for advanced or metastatic gastric cancer (GC)/ gastroesophageal junction (GEJ) cancer.
    Wang, Jianzheng
    He, Yunduan
    Zhang, Baiwen
    Cheng, Xiaojiao
    Li, Qingli
    Lv, Huifang
    Nie, Caiyun
    Chen, Beibei
    Xu, Weifeng
    Zhao, Jing
    Tu, Shuiping
    Chen, Xiaobing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16016 - E16016
  • [4] KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer
    Shitara, K.
    Ozguroglu, M.
    Bang, Y. J.
    Di Bartolomeo, M.
    Mandala, M.
    Ryu, M. H.
    Fornaro, L.
    Olesinski, T.
    Caglevic, C.
    Chung, H.
    Muro, K.
    Gokkurt, E.
    Mansoor, W.
    McDermott, R.
    Schacham-Shmueli, E.
    Chen, X.
    Kang, S. P.
    Mayo, C.
    Ohtsu, A.
    Fuchs, C.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [5] Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF)
    Chau, Ian
    Penel, Nicolas
    Arkenau, Hendrik-Tobias
    Santana-Davila, Rafael
    Calvo, Emiliano
    Soriano, Andres O.
    Mi, Gu
    Jin, Jin
    Ferry, David
    Herbst, Roy S.
    Fuchs, Charles S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [6] A phase II study of bevacizumab, docetaxel and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancer
    El-Rayes, B. F.
    Hammad, N.
    Philip, P. A.
    Shields, A. F.
    Heilbrun, L. K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
    Xu, Jian-Ming
    Liu, Rongrui
    Ba, Yi
    Jiang, Da
    Wang, Mingxia
    Zheng, Yulong
    Wei, Jia
    Bai, Yu-Xian
    Lin, Lizhu
    Xiong, Jianping
    Zhu, Xixi
    Zhao, Chuanhua
    Jia, Ru
    Zhang, Yun
    Liu, Jianzhi
    Zhang, Gairong
    Li, Guangze
    Wang, Quanren
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer.
    Chawla, Sant P.
    Chua, Victoria S.
    Gordon, Erlinda Maria
    Moradkhani, Ania
    Kim, Katherine
    Quon, Doris
    Wong, Steven
    Sumner, Robert
    Mac, Virginia
    Huang, Raymond
    Wang, Kelly
    Kim, Jiyeun
    Kim, Bumjin
    McGinn, Arlo N.
    Park, Cheol Hee
    Houston, Scott
    Sankar, Neil
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [9] Safety and efficacy of ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: a multi-disease phase 1 study
    Thuss-Patience, P.
    Vasile, E.
    Chau, I
    Penel, N.
    Mi, G.
    Emig, M.
    Fuchs, C. S.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 254 - 255
  • [10] Safety and antitumor activity from the phase lb study of ramucirumab plus pembrolizumab in treatment-naive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)
    Chau, I.
    Bendell, J.
    Soriano, A.
    Arkenau, H.
    Cultreras, J.
    Santana-Davila, R.
    Calvo, E.
    Le Toumeau, C.
    Zender, L.
    Mi, G.
    Schelman, W.
    Ferry, D.
    Herbst, R.
    Fuchs, C.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 122 - 122
12345